![Flavia Borellini](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Flavia Borellini
Direktor/Vorstandsmitglied bei
REVOLUTION MEDICINES, INC.
Vermögen: 5 Mio $ am 31.07.2026
Profil
Flavia Borellini currently works at Cantargia AB, as Independent Director from 2020, Revolution Medicines, Inc., as Independent Director from 2021, Kartos Therapeutics, Inc., as Director from 2018, and Pliant Therapeutics, Inc., as Independent Director from 2026.
Dr. Borellini also formerly worked at Acerta Pharma BV, as Chief Executive Officer from 2016 to 2019, Viracta Therapeutics, Inc., as Independent Director from 2021 to 2025, AstraZeneca PLC, as VP-Global Product & Portfolio Strategy from 2018 to 2020, Onyx Pharmaceuticals, Inc., as Vice President-Program Leadership from 2012 to 2013, and Roche Group, as Member.
Dr. Borellini received her doctorate degree from Università degli Studi di Modena e Reggio Emilia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.06.2026 | 26’215 ( 0.01% ) | 5 Mio $ | 31.07.2026 | |
| 09.07.2026 | 0 ( -.--% ) | - $ | 31.07.2026 |
Aktive Positionen von Flavia Borellini
| Unternehmen | Position | Beginn |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Direktor/Vorstandsmitglied | 22.06.2021 |
| CANTARGIA AB | Direktor/Vorstandsmitglied | 01.10.2020 |
| PLIANT THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 09.07.2026 |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Direktor/Vorstandsmitglied | 01.02.2018 |
Ehemalige bekannte Positionen von Flavia Borellini
| Unternehmen | Position | Ende |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 05.02.2025 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01.01.2020 |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Vorstandsvorsitzender | 01.02.2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01.10.2013 |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Corporate Officer/Principal | - |
Ausbildung von Flavia Borellini
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
59
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Università degli Studi di Modena e Reggio Emilia
 Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cantargia AB
 Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia | Health Technology |
Acerta Pharma BV
Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Develops drugs for oncology and autoimmune diseases | Health Technology |
Revolution Medicines, Inc.
 Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Pliant Therapeutics, Inc.
 Pliant Therapeutics, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company focuses on discovering and developing novel therapies for the treatment of fibrosis | Health Technology |
Kartos Therapeutics, Inc.
Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company that develops novel and targeted therapeutics | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
